HYQVIA
STN: BL 125402/0
Proper Name: Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase
Tradename: HYQVIA
Manufacturer: Takeda Pharmaceuticals U.S.A., Inc.
Indication:
- Indicated for the treatment of chronic inflammatory demyelinating polyneuropathy (CIDP) as maintenance therapy to prevent relapse of neuromuscular disability and impairment in adults.
Product Information
Supporting Documents
- January 12, 2024 Approval Letter - HYQVIA
- April 7, 2023 Approval Letter - HYQVIA
- April 7, 2023 Clinical Review Memo - HYQVIA
- April 7, 2023 Statistical Review Memo - HYQVIA
- Approval History, Letters, Reviews, and Related Documents - Hyqvia
- Supporting Documents older than three years - Hyqvia